PRKD1 and arthritic joint disease: Although more studies are necessary to sort those issues out, our results support the notion that PKD1 might be a reasonable new target for therapeutic intervention for arthritis, and that pharmacological inhibitors of PKD can be useful therapeutics for inflammatory arthritis, including RA.